‌

US Patent 9969787 Glucagon-like-peptide-2 (GLP-2) analogues

Patent 9969787 was granted and assigned to Zealand Pharma A/S on May, 2018 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors

Is a

0

Patent attributes

Patent Applicant

Zealand Pharma A/S

0

Current Assignee

Zealand Pharma A/S

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Kirsten Lindegaard Bovbjerg0

Wayne Shaun Russell0

Ditte Riber0

Rasmus Just0

Date of Patent

May 15, 2018

0

Patent Application Number

152381260

Date Filed

August 16, 2016

0

Patent Citations Received

US Patent 11884713 Acylated glucagon analogues

0

Patent Primary Examiner

0

Patent abstract

GLP-2 analogs are disclosed which comprise one of more substitutions as compared to h[Gly2]GLP-2 and which may have the property of an altered GLP-1 activity, and their medical use. The analogs are particularly useful for the prophylaxis treatment or ameliorating of the gastro-intestinal associated side effects of diabetes.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 9969787 Glucagon-like-peptide-2 (GLP-2) analogues

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool

By using this site, you agree to our Terms of Service.